sirolimus and Histiocytosis--Langerhans-Cell

sirolimus has been researched along with Histiocytosis--Langerhans-Cell* in 1 studies

Other Studies

1 other study(ies) available for sirolimus and Histiocytosis--Langerhans-Cell

Article	Year
BRAF Nature medicine, 2021, Volume: 27, Issue:5 Langerhans cell histiocytosis (LCH) is a potentially fatal condition characterized by granulomatous lesions with characteristic clonal mononuclear phagocytes (MNPs) harboring activating somatic mutations in mitogen-activated protein kinase (MAPK) pathway genes, most notably BRAF Topics: Animals; Apoptosis; Cell Proliferation; Cellular Senescence; Cytokines; Hematopoietic Stem Cells; Histiocytosis, Langerhans-Cell; Humans; Langerhans Cells; Mice; Mice, Inbred C57BL; Mice, Transgenic; Proto-Oncogene Proteins B-raf; Sirolimus; TOR Serine-Threonine Kinases	2021

Article

Year

Nature medicine, 2021, Volume: 27, Issue:5

Langerhans cell histiocytosis (LCH) is a potentially fatal condition characterized by granulomatous lesions with characteristic clonal mononuclear phagocytes (MNPs) harboring activating somatic mutations in mitogen-activated protein kinase (MAPK) pathway genes, most notably BRAF

Topics: Animals; Apoptosis; Cell Proliferation; Cellular Senescence; Cytokines; Hematopoietic Stem Cells; Histiocytosis, Langerhans-Cell; Humans; Langerhans Cells; Mice; Mice, Inbred C57BL; Mice, Transgenic; Proto-Oncogene Proteins B-raf; Sirolimus; TOR Serine-Threonine Kinases

2021